Selective apoptosis of natural killer-cell tumours by l-asparaginase

Miki Ando1, Koichi Sugimoto, Toshiyuki Kitoh

  • 1Department of Haematology, Juntendo University School of Medicine, Tokyo, Japan.

Insights

Natural killer (NK)-cell tumours are often chemotherapy-resistant. L-asparaginase effectively induced apoptosis in NK-cell lines and certain NK-cell disorders, showing promise for targeted therapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Natural killer (NK)-cell malignancies are often resistant to conventional chemotherapy.
  • Understanding differential drug sensitivity in NK-cell disorders is crucial for effective treatment.

Purpose of the Study:

  • To evaluate the efficacy of various anti-tumour agents against NK-cell tumour lines and patient samples.
  • To investigate the role of asparagine synthetase in drug response.
  • To differentiate NK-cell disorders and acute lymphoblastic leukemia (ALL) based on drug sensitivity.

Main Methods:

  • Flow cytometry and TUNEL assay to assess apoptosis.
  • Real-time quantitative PCR (RQ-PCR) and immunostaining for asparagine synthetase expression.
  • Drug sensitivity testing with l-asparaginase and doxorubicin (DXR).

Main Results:

  • NK-cell lines (NK-YS, NK-92) resistant to many agents, but sensitive to l-asparaginase.
  • NK-cell leukaemia/lymphoma and ALL samples showed selective sensitivity to l-asparaginase and DXR, respectively.
  • Chronic NK lymphocytosis samples were resistant to both drugs.
  • Correlation observed between asparagine synthetase levels, in vitro sensitivity, and clinical response to l-asparaginase in nasal-type NK-cell lymphoma.

Conclusions:

  • L-asparaginase demonstrates specific anti-tumour activity against NK-cell tumours in vitro.
  • Drug sensitivity profiles can distinguish between different NK-cell disorders and ALL.
  • Findings support the potential clinical use of l-asparaginase for treating NK-cell malignancies.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...